BDBM256621 US9481648, Ref Cpd A::US9790209, Example 2

SMILES Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3cc(C)c4[nH]ncc4c3)n2)c2ccccc12)C(C)(C)C#C

InChI Key InChIKey=JOUPQTNCMDHNRF-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 256621   

TargetCytochrome P450 3A4(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 1.50E+4nMAssay Description:Summary of CYP3A4 inhibition studies for various Compound Examples using 0 min preincubation.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 400nMAssay Description:Summary of CYP3A4 inhibition studies for various Compound Examples using 30 min preincubation.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 5.00E+3nMAssay Description:Summary of CYP2C9 inhibition studies for various Compound Examples using 0 min preincubation.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 1.40E+3nMAssay Description:Summary of CYP2C9 inhibition studies for various Compound Examples using 30 min preincubation.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 380nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 24nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 50nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent